THe effect of naloxone on spontaneous and evoked dopamine release in the central and peripheral nervous systems

Life Sciences

Volumn 59, Issue 24, 1996, Pages 2009-2019

  Feigenbaum, Jeffery J ^a   Howard, Sherrel G ^b  

^a Executive House ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

calcium uptake; central nervous system; dopamine release; intraterminal calcium influx; naloxone; peripheral nervous system

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; 3,4,5 TRIMETHOXYBENZOIC ACID 8 (DIETHYLAMINO)OCTYL ESTER; ACETYLCHOLINE; ALCOHOL; CALCIUM; CALCIUM ANTAGONIST; CARBACHOL; CLONIDINE; DEXAMPHETAMINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LANTHANUM; MORPHINE; N METHYL DEXTRO ASPARTIC ACID; NALOXONE; NIFEDIPINE; OPIATE; OPIATE ANTAGONIST; PHENCYCLIDINE; PHENETHYLAMINE; RADIOISOTOPE; SALSOLINOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; BEHAVIOR; BRAIN CORTEX; BRAIN REGION; CALCIUM TRANSPORT; CENTRAL NERVOUS SYSTEM; CORPUS STRIATUM; DOPAMINE RELEASE; INFUNDIBULUM; NONHUMAN; NUCLEUS ACCUMBENS; PERIPHERAL NERVOUS SYSTEM; RETINA; REVIEW;

ANIMALIA;

EID: 0030575804     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(96)00399-2     Document Type: Short Survey

References (129)

1. 1. S.G. HOLTZMAN, J Pharmacol. Exp. Ther 189 51-80 (1974)
2. 2. S.E. DeROSSETT and S.G. HOLTZMAN, Pharmacol. Biochem. Behav. 17 341-351 (1982)
3. 3. D.N. JONES and S.G. HOLTZMAN, J. Pharmacol. Exp. Ther. 262 638-645 (1992)
4. 4. M.J. NG CHEONG TON, R. BLAIR, L. HOLMES and Z. AMIT, Subst. Alcohol Act./Misuse, 4 331-336 (1983)
5. 5. S.G. HOLTZMAN, Psychopharmacologia 39 23-37 (1974)
6. 6. P.W. DETTMAR, A. COWAN and D.S. WALTER, Neuropharmacology 17 1041-1044 (1978)
7. 7. B.I. DIAMOND and R.L. BORISON, Neurology 28 1085-1088 (1978)
8. 8. S. FULGENITTI and L. CANCELA, Psychopharmacology 79 45-48 (1983)
9. 9. M. SKORUPSKA and R. LANGWINSKI, Pol. J. Pharmacol. Pharm. 41 401-411 (1989)
10. 10. S. HABER, T. HATSUKAMI, P.A. BERGER, J.D. BARCHAS and H. AKIL, Prog. Neuropsychopharmacol. 2 425-430 (1978)
11. 11. R.J. KATZ, B.J. CARROL, G. BALDRIGHI, Pharmacol. Biochem. Behav. 8 493-496 (1978)
12. 12. K.A. ROTH, R.J. KATZ, K. SCHMATLZ and M. SIBEL, Int. J. Neurosci. 12 59-62 (1981)
13. 13. C.P. DOKLA, Pharmacol. Biochem. Behav. 43 1183-1193 (1992)
14. 14. S. AMIR, M. SOLOMON and Z. AMIT, Neuropharmacology 18 171-173 (1979)
15. 15. S.E. FILE, Psychopharmacology 71 41-44 (1980)
16. 16. M. UKAI and T. KAMEYAMA, Brain Res. 328 378-380 (1985)
17. 17. M.L. BILLINGSLEY and R.K. KUBENA, Life Sci. 22 897-906 (1978)
18. 18. J.J. BILLINGS, KUNG, M.P., CHUMPRADIT, S., MOZLEY, D., ALAVI, A. and KUNG, H.F., J. Neurochem. 58 227-236 (1992)
19. 19. R.M. KESSLER, M.S. ANSARI, D.E. SCHMIDT, T. de PAULIS, J.A. CLANTON, R. INNIS, M. AL-TIKRITI, R.G. MANNING and D. GILLESPIE, Life Sci. 49 617-628 (1991)
20. 20. K.R. CARLSON and T.F. SEEGER, Pharmacol. Biochem. Behav. 16 119-124 (1982)
21. 21. A. CZLONKOWSKI, V. HOLLT and A. HERZ, Life Sci. 22 953-962 (1978)
22. 22. R.S. ROOT-BERNSTEIN, Brain Res. Bull. 18 509-532 (1987)
23. 23. J.J. FEIGENBAUM, J. YANAI, C. ISER and H.L. KLAWANS, Neuropsychobiology 11 94-97 (1984)
24. 24. C.A. SCHAD, J.B. JUSTICE JR., and S.G. HOLTZMAN, Soc. Neurosci. Abstr. 19 184 (1992)
25. 25. M.S. HOOKS, D.N. JONES, J.B. JUSTICE JR., and S.G. HOLTZMAN, Pharmacol. Biochem. Behav. 42 765-770 (1992)
26. 26. I. IZQUIERDO and N. GRAUDENEZ, Psychopharmacology 67 265-268 (1980)
27. 27. S. FULGENITTI and L. CANCELA, Psychopharmacology 79 45-48 (1983)
28. 28. J.J. FEIGENBAUM, J. YANAI, B.H. MOON, and H.L. KLAWANS, Neuropharmacology 22 1369-1376 (1983)
29. 29. J.J. BALSARA, N.V. NANDAL, N.P. BURTE, J.H. JADHAV and A.G. CHANDORKAR, Psychopharmacology 82 237-240 (1984)
30. 30. P.M. ADAMS, R. BEAUCHAMP and C. ALSTON, Life Sci. 28 629-634 (1981)
31. 31. S.G. MOYANOVA and S.P. ROUSSEVA, Acta Physiol. Bulg. 15 47-52 (1989)
32. 32. P.A. BRODERICK, C.D. BLAHA and R.F. LANE, Behav. Brain Res. 24 31-38 (1987)
33. 33. D.N. JONES and S.G. HOLTZMAN, J. Pharmacol. Exp. Ther. 262 638-645 (1992)
34. 34. C. MALMNAS, J. Endocrinol. 73 187-188 (1979)
35. 35. G. GESSA and A. TAGLIAMONTE, Psychopharmacology, Sexual Disorders and Drug Abuse, T.A. Ban (ed), 451-462, North Holland, Amsterdam (1973)
36. 36. F. FERRARI and G. BAGGIO, Eur. J. Pharmacol. 81 321-326 (1982)
37. 37. A. HORITA and M. CARINO, Life Sci. 23 1681-1686 (1978)
38. 38. J.B. MALICK, M.L. BILLINGSLEY, R.K. KUBENA and J. M. GOLDSTEIN, Comm. Psychopharmcol. 1 475-488 (1977)
39. 39. C.T. DOURISH and S.J. COOPER, Neuropharmacology 23 1059-1064 (1984)
40. 40. K. VEREBEY, M.J. KOGAN and S.J. MULE, Psychopharmacology 75 44-47 (1981)
41. 41. M. SKORUPSKA and R. LANGWINSKI, Pol. J. Pharmacol. Pharm. 41 401-411 (1989)
42. 42. Z.-H. GALINA and Z. AMIT, Prog. Neuro-Psychopharm. Biochem. Behav. 31 371-373 (1988)
43. 43. S. FASSINO, E. TORRE and B. VARETTO, Boll. Soc. Ital. Biol. Sper. 58 1467-1471 (1982)
44. 44. M. SANSONE and J. VETULANI, Pharmacol. Biochem. Behav. 31 371-373 (1988)
45. 45. H.O.J. COLLIER, D.L. FRANCIS, G. HENDERSON and C. SCHNEIDER, Nature 249 471-47 (1974)
46. 46. C. PINSKY, Characteristics and Functions of Opiates, J.M. Van Rees and L. Terenius (eds), 430-440, Elsevier-North Holland, Amsterdam, (1978)
47. 47. I. GORRIS and J.H. VAN ABEELEN, Psychopharmacology 74 355-359 (1981)
48. 48. K. KUSCHINSKY and O. HORNYKIEWICZ, Eur. J. Pharmacol. 19 119-122 (1972)
49. 49. R.H. HITZEMANN, H.H. LOH and E.L. WAY, Proc. West. Pharmacol. Soc. 14 91-94 (1971)
50. 50. C. GAUCHY, M. DESBAN, M.O. KREBS, J. GLOWINSKI and M.L. KEMEL, Neuroscience 41 449-458 (1991)
51. 51. M.L. KEMEL, M. DESBAN, J. GLOWINSKI, C. GAUCHY, Neuroscience 50 597-610 (1992)
52. 52. M.O. KREBS, C. GAUCHY, M. DESBAN, J. GLOWINSKI and M.L. KEMEL, J. Neurosci. 14 2435-2443 (1994)
53. 53. J.J. FEIGENBAUM, J. YANAI, C. ISER, and H.L. KLAWANS, Neuropsychobiology 11 94-97 (1984)
54. 54. N.J. LAPING, D.E. DLUZEN and V.D. RAMIREZ, Neurobiol. Aging 11 395-399 (1990)
55. 55. R.B. HOLMAN, B.M. SNAPE and P.S. WIDDOWSON, Alcoh. Alcoholism, Suppl. 1 737-741 (1987)
56. 56. M.S. REID, M. HERRERA-MARSCHITZ and U. UNGERSTEDT, Neuroscience 36 659-667 (1990)
57. 57. U. KISCHKA, S.A. FARBER, D. MARSHALL and R.J. WURTMAN, Brain Res. 613 288-290 (1993)
58. 58. F. DAUDET, V. LEVIEL, C. KERNY, B. GUIBERT and C. BARBEERIS, Eur. J. Pharmacol. 95 199-205 (1983)
59. 59. M.F. CHESSELET, A. CHERAMY, T.D. REISINE, C. LUBETZKI, M. DESBAN and J. GLOWINSKI, Brain Res 258 229-242 (1983)
60. 60. T.C. WESTFALL, C.A. DIFAZIO, and J. SAUNDERS, Anaesthesiology 48 118-124 (1978)
61. 61. H.E. SAVAKI, J.A. GIRAULT, U. SPAMPINATO, N.A. TROUONG, J. GLOWINSKI and M.J. BESSON, Brain Res. Bull. 16 149-154 (1986)
62. 62. L. STAHLE, A.-K. COLLIN and U. UNGERSTEDT, Naunyn-Schmied. Arch. Pharmacol. 342 136-140 (1990)
63. 63. G. MEREU, B. FANNI, and G.L. GESSA, Catecholamines: Neuropharmacology and Central Nervous System - Theoretical Aspects, E. Usdin, A. Carlsson, A. Dahlstrom and J. Engels (eds), 353-358, Liss Publishing Inc., New York (1984)
64. 64. U. SPAMPINATO, J.-A. GIRAULT, J. DANGUIR, H.E. SAVAKI, J. GLOWINSKI and M.-J. BESSON, Brain Res. Bull. 16 161-166 (1986)
65. 65. G. MEREU, F. FADDA and G.L. GESSA, Brain Res. 292 63-69 (1984)
66. 66. R. SPANAGEL, A. HERZ, R. BALS-KUBIK and T.S. SHIPPENBERG, Psychopharmacology 104 51-56 (1991)
67. 67. W.J. MERRELL, L. GORDON, A.J. WOOD, S. SHAY, E. JACKSON and M. WOOD, Anaesthesiology 72 308-314 (1990)
68. 68. H. HERDON, J. STRUPISH and S.R. NAHORSKI, Brain Res. 348 309-320 (1985)
69. 69. K. JHAMANDAS and M.R. MARIEN, Br. J. Pharmacol. 90 641-650 (1987)
70. 70. M.S. STARR Presynaptic Regulation of Neurotransmitter Release: A Handbook, J.J. Feigenbaum and M. Hanani (eds), Vol. 2, 613-649, London, Freund Publishing Ltd. (1991)
71. 71. P.W. KALIVAS and R. RICHARDSON-CARLSON, Am. J. Physiol. 251 R243-R249 (1986)
72. 72. B. COSTALL, S-CG HUI and R.J. NAYLOR, Neuropharmacology 19 1039-1048 (1980)
73. 73. B. COSTALL, A.M. DOMENEY and R.J. NAYLOR, Psychopharmacolgy 82 174-180 (1984)
74. 74. A.J.J. PIJNENBURG, W.M.M. HONIG, J.A.M. VAN DER HAYDEN and J.M. VAN ROSSUM, Eur. J. Pharmacol. 35 49-58 (1976)
75. 75. E.M. JOYCE and S.D. IVERSEN, Psychopharmacology 83 363-366 (1984)
76. 76. C.A. LEADEM, W.R. CROWLEY, J.W. SIMPKINS and S.P. KALRA, Neuroendocrinology 40 497-500 (1985)
77. 77. M.M. WILKES and S.S.C. YEN, Life Sci. 27 1387-1391 (1980)
78. 78. M.M. WILKES and S.S.C. YEN, Life Sci. 28 2355-2359 (1981)
79. 79. H. KOSHIYAMA, Y. KATO, A. SHIMATSU and H. IMURA, Neurosci. Lett. 99 328-332 (1989)
80. 80. P.S. WIDDOWSON and R.B. HOLMAN, J. Neurochem. 59 157-163 (1992)
81. 81. A. SEILCOVICH, M. RUBIO, B. DUVILANSKI V. M. MAINES and V. RETTORI, Psychopharmacology 87 461-463 (1985)
82. 82. P.S. KALRA W.R. CROWLEY and S.P. KALRA, Endocrinology 120 178-185 (1987)
83. 83. D.D. RASMUSSEN, B.P. KENNEDY, M.G. ZIEGLER and T.M. NETT, Endocrinology 123 2916-2921 (1988)
84. 84. P.A. GARRIS and N. BEN JONATHON, Neuroendocrinology 52 399-404 (1990)
85. 85. E. BOHM, E. MUSCHOLL and K. RACKE, Br. J. Pharmacol. 86 534P (1985)
86. 86. K. RACKE, E. BOHM, S. HURTH and E. MUSCHOLL, Life Sci. 38 1749-1756 (1986)
87. 87. W. KOLBINGER and R. WEILER, Visual Neurosci. 10 1035-1041 (1993)
88. 88. M.L. DUBOCOVICH and N. WEINER, J. Pharmacol. Exp. Ther. 224 634-639 (1983)
89. 89. A.I. FADEN, T.P. JACOB, G. FEUERSTEIN and J.W. HOLADAY, Brain Res. 213 415-421 (1981)
90. 90. H.M. RHEE and D.W. HENDRIX, Prog. Clin. Biol. Res. 328 497-500 (1990)
91. 91. L.J. EDDY, D.W. JOINER and T.M. GLENN, Res. Comm. Chem. Path. Pharmacol. 43 113-125 (1984)
92. 92. Y. MASUBUCHI, T. KUMAI, M. TANAKA and M. WATANABE, Nippon Yakur. Zasshi 98 83-90 (1991)
93. 93. R.G. MCMURRAY, E. NEWBOULD, P. BOULOUX, G.M. BESSER and A. GROSSMAN, Psychoneuroendocrinology 16 447-455 (1991)
94. 94. C. SAITO, R. CALVET, X. GUITART, C. SOLSONA and J. MARSAL, Toxicol. Appl. Pharmacol., 106 20-27 (1990)
95. 95. J.M. CROWDER, D.K. NORRIS and H.F. BRADFORD, Biochem. Pharmacol. 35 2501-2507 (1986)
96. 96. D.M. MICHAELSON, G. MCDOWALL and Y. SARNE, J. Neurochem. 43 614-618 (1984)
97. 97. T. KAKUNAGA, H. KANETO and K. HANO, J. Pharmacol. Exp. Ther. 153 134-141 (1966)
98. 98. T. KAKUNAGA, H. KANETO and K. HANO, Folio Pharmacol. Jap. 62 31-50 (1966)
99. 99. M. KAVALIERS, Brain Res 408 403-407 (1987)
100. 100. C.H. LEE and B.A. BERKOWITZ, J. Pharmacol. Exp. Ther. 198 347-356 (1976)
101. 101. C. ELA, Y. HASIN, and Y. EILAM, J. Mol. Cell. Cardiol. 25: 599-613 (1993)
102. 102. S. RAMASWAMY, S.K. NAZIMUDEEN, and L. KAMESWARAM, J. Pharm. Pharmacol. 31 222-223 (1979)
103. 103. P. NAGY-KERESZTES and J.P. ROSENFELD, Brain Res. 208 234-239 (1981); see also J. RABKIN, Clin. Exp. Pharmacol. Physiol. 18 431-438 (1991)
104. 103. P. NAGY-KERESZTES and J.P. ROSENFELD, Brain Res. 208 234-239 (1981); see also J. RABKIN, Clin. Exp. Pharmacol. Physiol. 18 431-438 (1991)
105. 104. S.P. WELCH and W.L. DEWEY, J. Pharmacol. Exp. Ther. 239 320-326 (1990)
106. 105. D.H. ROSS, M.A. MEDINA and H. L. CARDENAS, Science 186 63-64 (1974)
107. 106. K. BLUM, S. FUTTERMAN, J.F. WALLACE and H.A. SCHWERTER, Nature 265 49-51 (1977)
108. 107. P. ADAMSON, J.Z. XIANG, T. MANTZOURIDES, M.J. BRAMMER and I.C. CAMPBELL, Eur. J. Pharmacol. 174 63-70 (1989)
109. 108. M. MANELLI, M. MAGGI, M. DE FEO, S. CUOMO, G. FORTI, F. MORONI and G. GIUSTI, New Engl. J. Med. 308 654-655 (1983)
110. 109. B.T. STOKES, G. HOLLINDEN and P. FOX, Brain Res. 290 187-190 (1984)
111. 110. H. B. TAUBE, E. BOROWSKI, T. ENDO and K. STARKE, Eur. J. Pharmacol. 38 377-380 (1976)
112. 111. H.M. RHEE and D.W. HENDRIX, The International Narcotics Research Conference '89, 497-500, New York, Alan R. Liss, Inc. (1990)
113. 112. J.J. BUCCAFUSCO, D.C. MARSHALL, and R.M. TURNER, Life Sci. 35 1401-1408 (1984)
114. 113. H.F. BRADFORD, Regulatory Mechanisms of Syanptic Transmission, R. Tapia and C.W. Cotman (eds), 126-135, Plenum Press, New York (1981)
115. 114. J.C. NETTO, A. GHANI and H.F. BRADFORD, Biochem. Pharmacol. 29 2777-27 (1980)
116. 115. M.M. DADDONA and J. HALDAR, Soc. Neurosci. Abstr. 17 980 (1991)
117. 116. G. DAYANITHI, E.L. STUENKEL, J.J. NORDMANN, Exp. Brain Res. 90: 539-545 (1992)
118. 117. W.F. SIMONDS, A.M. BOOTH, K.B. THOR, N.L. OSTROWSKI, J.R. NAGEL and W.C. De GROAT, Brain Res. 271 365-370 (1983)
119. 118. P.F. VON VOIGHTLANDER, M.C. OCHOA and R.A. LEWIS, Adv. Exp. Med. Biol. 221 345-355 (1987)
120. 119. J. SAWYNOK, C. PINSKY and F.S. LABELLA, Life Sci. 25 1621-1632 (1979)
121. 120. S.M. JOHNSON, D.P. WESTFALL, S.A. HOWARD and W.W. FLEMING, J. Pharmacol. Exp. Ther. 204 54-66 (1978)
122. 121. E. DORA, K. HINES, G. KUNOS and A.C. MCLAUGHLIN, Brain Res. 573 293-298 (1992)
123. 122. T. V. DUNWIDDIE, E. PEREZ-REYES, K.C. RICE and M.R. PALMER, Neuroscience 7 1691-1702 (1982)
124. 123. M. KASCHUBE and H. BRASCH, Cardiovas. Res. 25 230-234 (1991)
125. 124. J. A. WHITTAKER, D.C. BERNARD, P.W. ARCHER and C.O. TROUTH, Soc. Neurosci. Abstr. 11 1143 (1985)
126. 125. N.L. OSTROWSKI and A.R. CAGGUILA, J. Pharmacol. Exp. Ther. 257 72-81 (1991)
127. 126. S. AMIR, Brain Res. 290 191-194 (1984)
128. 127. M.J. KATOVICH, C.C. BARNEY and E. LARSEN, Pharmacology 41 167-176 (1990)
129. 128. J.M. VAN NUETEN, J.M. VAN REE and P.M. VANHOUTTE, Eur. J. Pharmacol. 41 341-342 (1977)